Autoimmune Hepatitis

Hepatitis is a general term that means inflammation of the liver. In Autoimmune Hepatitis, the body's immune system attacks the cells of the liver, which causes the liver to become inflamed.

Most patients with Autoimmune Hepatitis have no symptoms. The disorder is often first detected by abnormal liver function tests found in blood testing (such as for a life insurance examination).

For the more severe cases of the disease, the most common symptom is fatigue. Some people also have symptoms of Hepatitis such as fever and jaundice (yellowing of the skin or eyes or dark urine). Other symptoms include itching, skin rashes, joint pain, abdominal discomfort, abnormal blood vessels in the skin, nausea and vomiting and loss of appetite.

In its most advanced form, Autoimmune Hepatitis can progress to cirrhosis (scarring of the liver).

If you display any of the above symptoms, please consult a liver doctor (Hepatologist) to confirm the diagnosis and to manage the condition.

Autoimmune Hepatitis is diagnosed through blood tests and a liver biopsy. During a liver biopsy, a small sample of liver tissue is removed with a needle and examined under a microscope.

It is not clear why Autoimmune Hepatitis develops. Researchers suspect that some people inherit a genetic disposition that could make them more likely to develop it.

Sometimes drugs or infections trigger the development of the disease. Patients with Autoimmune Hepatitis may also have other autoimmune disorders, such as thyroiditis (inflammation of the thyroid), ulcerative colitis (inflammation of the bowel), diabetes mellitus, vitiligo (patches of skin discoloration), lupus, or Sjögren's syndrome (inflammation of the salivary and tear glands).

Autoimmune Hepatitis is diagnosed with blood tests and a liver biopsy. During a liver biopsy, a small sample of liver tissue is removed with a needle and examined under a microscope.

Autoimmune Hepatitis is usually treated first with steroids (such as prednisone). Prednisolone at a high dosage, during long-term treatment, can lead to weight gain, bone loss, elevated blood glucose levels (potentially leading to diabetes), an increased risk of infections, cataracts, high blood pressure, mood and sleep disturbance.

As a general rule, treatment should continue until blood profiles of the liver are normal and there is an absence of liver inflammation.

Approximately 65 and 80 percent of patients achieve remission within 18 months and three years respectively. About 50 percent of patients remain in remission or have only mild disease activity for months to years after treatment is stopped. However, patients whose disease relapses or becomes active again may have to restart treatment.

A relapse typically occurs within the first 15 to 20 months after treatment is stopped ,and is more likely in those who have cirrhosis on the initial liver biopsy.